|
|
Blood, 5 March 2009, Vol. 113, No. 10, pp. 2202-2212.
Prepublished online as a Blood First Edition Paper on October 24, 2008; DOI 10.1182/blood-2008-06-162594.
Previous Article | Table of Contents | Next Article 
HEMATOPOIESIS AND STEM CELLS
PIAS3 negatively regulates RANKL-mediated osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblasts
Tomohiro Hikata1,
Hironari Takaishi1,
Jiro Takito1,
Akihiro Hakozaki1,
Mitsuru Furukawa1,
Shinichi Uchikawa1,
Tokuhiro Kimura2,
Yasunori Okada2,
Masahito Matsumoto3,
Akihiko Yoshimura4,
Riko Nishimura5,
Sakamuri V. Reddy6,
Hiroshi Asahara7, and
Yoshiaki Toyama1
Departments of 1 Orthopaedic Surgery and
2 Pathology, School of Medicine, Keio University, Tokyo, Japan;
3 Department of Molecular Biology, Saitama Medical School, Saitama, Japan;
4 Department of Microbiology and Immunology, School of Medicine, Keio University, Tokyo, Japan;
5 Department of Molecular and Cellular Biochemistry, Osaka University, Osaka, Japan;
6 Children's Research Institute, Medical University of South Carolina, Charleston; and
7 Department of Innovative Surgery, National Center for Child Health and Development, Tokyo, Japan
Cytokine signaling via various transcription factors regulates receptor activator of nuclear factor (NF)– B ligand (RANKL)–mediated osteoclast differentiation from monocyte/macrophage lineage cells involved in propagation and resolution of inflammatory bone destruction. Protein inhibitor of activated STAT3 (PIAS3) was initially identified as a molecule that inhibits DNA binding of STAT3 and regulates many transcription factors through distinct mechanisms. To analyze PIAS3 function in osteoclasts in vivo, we have generated transgenic mice in which PIAS3 is specifically expressed in the osteoclast lineage using the tartrate-resistant acid phosphatase (TRAP) gene promoter. PIAS3 transgenic mice showed an osteopetrotic phenotype due to impairment of osteoclast differentiation. Overexpression of PIAS3 in RAW264.7 cells suppressed RANKL-induced osteoclastogenesis by inhibiting the expression of c-Fos and NFATc1. Interestingly, PIAS3 inhibits the transcriptional activity of microphthalmiaassociated transcription factor (MITF) independent of sumoylation. Down-regulation of PIAS3 markedly enhances RANKL-mediated osteoclastogenesis in RAW264.7 cells. Furthermore, overexpression of PIAS3 in mouse primary osteoblast (POB), down-regulates RANKL expression induced by interleukin-6 (IL-6) cytokine family, and inhibits osteoclast formation from bone marrow macrophages (BMMs) in vitro coculture system. Down-regulation of PIAS3 leads to the accelerated expression of RANKL in POB stimulated with IL-6 and soluble IL-6 receptor (sIL-6R). Taken together, our results clearly indicate that PIAS3 negatively regulates RANKL-mediated osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblasts.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Furukawa, H. Takaishi, J. Takito, M. Yoda, S. Sakai, T. Hikata, A. Hakozaki, S. Uchikawa, M. Matsumoto, K. Chiba, et al.
IL-27 Abrogates Receptor Activator of NF-{kappa}B Ligand-Mediated Osteoclastogenesis of Human Granulocyte-Macrophage Colony-Forming Unit Cells through STAT1-Dependent Inhibition of c-Fos
J. Immunol.,
August 15, 2009;
183(4):
2397 - 2406.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|